Clinical trials included adults up to their mid-70s, and weight loss benefits were seen across age groups. There’s limited evidence directly comparing older versus younger adults, but no major differences in effectiveness have been noted, though older people may be more sensitive to side effects. Who was included in the trials The large clinical trials of semaglutide, such as the STEP programme, included adults with overweight or obesity up to about 75 years old. This means w

Many people on Wegovy report fewer food cravings and better control over eating, which can reduce stress around meals. Other drugs like...

Wegovy is made as a biologic medicine, meaning it uses recombinant technology to produce semaglutide, a protein-based drug. Mysimba and Orlistat, by contrast, are small-molecule tablets made by chemical synthesis. These differences influence regulation and supply but not day-to-day use for patients. What makes Wegovy a biologic Wegovy (semaglutide) belongs to a group of medicines known as biologics. These are typically large, complex molecules produced in living cells using r

Both contain semaglutide and improve blood sugar by enhancing insulin release and reducing glucagon. Ozempic is specifically licensed for...

Both contain semaglutide and improve blood sugar by enhancing insulin release and reducing glucagon. Ozempic is specifically licensed for diabetes at lower doses, while Wegovy provides the same benefits at higher doses alongside more pronounced weight reduction. How semaglutide works on blood sugar Semaglutide, the active ingredient in both Wegovy and Ozempic, belongs to the GLP-1 receptor agonist family. It lowers blood sugar by stimulating insulin release when glucose level

Wegovy is made as a biologic medicine, meaning it uses recombinant technology to produce semaglutide, a protein-based drug. Mysimba and...

Yes — trials show Wegovy users lose more weight earlier than with Saxenda, thanks to its stronger appetite effect and weekly dosing. That...

Yes — trials show Wegovy users lose more weight earlier than with Saxenda, thanks to its stronger appetite effect and weekly dosing. That said, both require steady use over months for results to build. The two medicines at a glance Wegovy and Saxenda belong to the same family of medicines, GLP-1 receptor agonists. They help people feel fuller sooner, reduce appetite, and support healthier eating. The difference lies in the active ingredient and how they are dosed: Wegovy cont

In many cases, Wegovy can be used as the main weight loss medicine, especially when diet and exercise alone haven’t worked. However, switching or replacing other drugs should always be guided by a clinician, as some combinations may still be appropriate depending on health needs. Wegovy as a first-choice option Since its approval by NICE in 2023, Wegovy (semaglutide 2.4 mg weekly) has become the leading option for medical weight management in the UK. Clinical evidence from th

In many cases, Wegovy can be used as the main weight loss medicine, especially when diet and exercise alone haven’t worked. However,...

Both Wegovy (semaglutide 2.4 mg) and Trulicity (dulaglutide) improve blood sugar, but semaglutide generally produces greater reductions...

Both Wegovy (semaglutide 2.4 mg) and Trulicity (dulaglutide) improve blood sugar, but semaglutide generally produces greater reductions in HbA1c and body weight. NICE recommends semaglutide more widely for people needing weight-focused management. Two GLP-1 medicines, one key difference Wegovy and Trulicity both belong to the GLP-1 receptor agonist family of medicines. They mimic the hormone GLP-1, which reduces appetite, slows digestion, and stimulates insulin release when b

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other medicines have different risks: Orlistat can cause oily stools, Mysimba may raise blood pressure, and phentermine (not used in the UK) carries cardiovascular risks. Understanding risk in context All weight-loss medicines come with benefits and risks. Doctors weigh these carefully before prescribing, taking into account a person’s health conditio

Yes, Wegovy has strong evidence in people with type 2 diabetes, cardiovascular disease, and sleep apnoea, where weight loss can improve outcomes. Other drugs may be chosen if semaglutide is unsuitable, but few have shown the same range of benefits across multiple health conditions. Why certain conditions matter Weight-related health problems often go beyond the number on the scales. People with obesity are more likely to develop type 2 diabetes, cardiovascular disease, and sl

Yes, Wegovy has strong evidence in people with type 2 diabetes, cardiovascular disease, and sleep apnoea, where weight loss can improve...

The most common side effects with Wegovy are gastrointestinal, such as nausea and diarrhoea, and these often lessen over time. Other...

The SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced the risk of major heart problems in people with overweight or obesity and...

No, even though both contain semaglutide, they are licensed for different uses and come in different devices and doses. Doctors may...

The SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced the risk of major heart problems in people with overweight or obesity and cardiovascular disease. Orlistat, while useful for modest weight loss, has not shown the same scale of cardiovascular benefits in large outcome studies. Two very different medicines Wegovy and Orlistat are both prescribed for weight management, but they work in completely different ways. Wegovy (semaglutide) is a GLP-1 receptor agonist that red

No, even though both contain semaglutide, they are licensed for different uses and come in different devices and doses. Doctors may...